[1] UNAIDS. AIDS epidemic update[OL]. https://www.unaids.org/sites/default/files/media_asset/2020_aids-data-book_en.pdf. 2020.
[2] DALGLEISH A G. The pathogenesis of AIDS:classical and alternative views[J]. J R Coll Physicians Lond, 1992, 26(2):152-158.
[3] TSIBRIS A M, HIRSCH M S. Antiretroviral therapy in the clinic[J]. J Virol, 2010, 84(11):5458-5464.
[4] PALELLA JR F J, DELANEY K M, MOORMAN A C, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators[J]. N Engl J Med, 1998, 338(13):853-860.
[5] GONZÁLEZ-SCARANO F, MARTÍN-GARCÍA J. The neuropathogenesis of AIDS[J]. Nat Rev Immunol, 2005, 5(1):69-81.
[6] BHASKARAN K, MUSSINI C, ANTINORI A, et al. Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy[J]. Ann Neurol, 2008, 63(2):213-221.
[7] ELLERO J, LUBOMSKI M, BREW B. Interventions for neurocognitive dysfunction[J]. Curr HIV/AIDS Rep, 2017, 14(1):8-16.
[8] ELBIRT D, MAHLAB-GURI K, BEZALEL-ROSENBERG S, et al. HIV-associated neurocognitive disorders (HAND)[J]. Isr Med Assoc J, 2015, 17(1):54-59.
[9] HEATON R K, CLIFFORD D B, FRANKLIN JR D R, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy:CHARTER Study[J]. Neurology, 2010, 75(23):2087-2096.
[10] ELLIS R J, DEUTSCH R, HEATON R K, et al. Neurocognitive impairment is an independent risk factor for death in HIV infection. San diego HIV neurobehavioral research center group[J]. Arch Neurol, 1997, 54(4):416-424.
[11] RAGIN A B, DU H Y, OCHS R, et al. Structural brain alterations can be detected early in HIV infection[J]. Neurology, 2012, 79(24):2328-2334.
[12] WANG B, LIU Z Y, LIU J J, et al. Gray and white matter alterations in early HIV-infected patients:Combined voxel-based morphometry and tract-based spatial statistics[J]. J Magn Reson Imaging, 2016, 43(6):1474-1483.
[13] RAGIN A B, WU Y, GAO Y, et al. Brain alterations within the first 100 days of HIV infection[J]. Ann Clin Transl Neurol, 2015, 2(1):12-21.
[14] LI Y F, LI H J, GAO Q S, et al. Structural gray matter change early in male patients with HIV[J]. Int J Clin Exp Med, 2014, 7(10):3362-3369.
[15] THOMPSON P M, DUTTON R A, HAYASHI K M, et al. Thinning of the cerebral cortex visualized in HIV/AIDS reflects CD4+T lymphocyte decline[J]. Proc Natl Acad Sci U S A, 2005, 102(43):15647-15652.
[16] SANFORD R, FELLOWS L K, ANCES B M, et al. Association of brain structure changes and cognitive function with combination antiretroviral therapy in HIV-positive individuals[J]. JAMA Neurol, 2018, 75(1):72-79.
[17] ANCES B M, ORTEGA M, VAIDA F, et al. Independent effects of HIV, aging, and HAART on brain volumetric measures[J]. J Acquir Immune Defic Syndr, 2012, 59(5):469-477.
[18] UNDERWOOD J, COLE J H, CAAN M, et al. Gray and white matter abnormalities in treated human immunodeficiency virus disease and their relationship to cognitive function[J]. Clin Infect Dis, 2017, 65(3):422-432.
[19] TESIC T, BOBAN J, BJELAN M, et al. Basal ganglia shrinkage without remarkable hippocampal atrophy in chronic aviremic HIV-positive patients[J]. J Neurovirol, 2018, 24(4):478-487.
[20] CLIFFORD K M, SAMBOJU V, COBIGO Y, et al. Progressive brain atrophy despite persistent viral suppression in HIV patients older than 60 years[J]. J Acquir Immune Defic Syndr, 2017, 76(3):289-297.
[21] VAN ZOEST R A, UNDERWOOD J, DE FRANCESCO D, et al. Structural brain abnormalities in successfully treated HIV infection:associations with disease and cerebrospinal fluid biomarkers[J]. J Infect Dis, 2017, 217(1):69-81.
[22] NIR T M, JAHANSHAD N, CHING C R K, et al. Progressive brain atrophy in chronically infected and treated HIV+individuals[J]. J Neurovirol, 2019, 25(3):342-353.
[23] CARDENAS V A, MEYERHOFF D J, STUDHOLME C, et al. Evidence for ongoing brain injury in human immunodeficiency virus-positive patients treated with antiretroviral therapy[J]. J Neurovirol, 2009, 15(4):324-333.
[24] CORRÊA D G, ZIMMERMANN N, TUKAMOTO G, et al. Longitudinal assessment of subcortical gray matter volume, cortical thickness, and white matter integrity in HIV-positive patients[J]. J Magn Reson Imaging, 2016, 44(5):1262-1269.
[25] CORRÊA D G, ZIMMERMANN N, VENTURA N, et al. Longitudinal evaluation of resting-state connectivity, white matter integrity and cortical thickness in stable HIV infection:Preliminary results[J]. Neuroradiol J, 2017, 30(6):535-545.
[26] SANFORD R, ANCES B M, MEYERHOFF D J, et al. Longitudinal trajectories of brain volume and cortical thickness in treated and untreated primary human immunodeficiency virus infection[J]. Clin Infect Dis, 2018, 67(11):1697-1704.
[27] CHANG L, SHUKLA D K. Imaging studies of the HIV-infected brain[J]. Handb Clin Neurol, 2018, 152:229-264.
[28] DAHNKE R, YOTTER R A, GASER C. Cortical thickness and central surface estimation[J]. Neuroimage, 2013, 65:336-348.
[29] ASHBURNER J, FRISTON K J. Unified segmentation[J]. Neuroimage, 2005, 26(3):839-851.
[30] CAI W Q, WANG Y J. Advances in construction of human brain atlases from magnetic resonance images[J]. Chinese J Magn Reson, 2020, 37(2):241-453.蔡文琴,王远军.基于磁共振成像的人脑图谱构建方法研究进展[J].波谱学杂志, 2020, 37(2):241-253.
[31] CASTELO J M, COURTNEY M G, MELROSE R J, et al. Putamen hypertrophy in nondemented patients with human immunodeficiency virus infection and cognitive compromise[J]. Arch Neurol, 2007, 64(9):1275-1280.
[32] HEAPS J M, SITHINAMSUWAN P, PAUL R, et al. Association between brain volumes and HAND in cART-naïve HIV+individuals from Thailand[J]. J Neurovirol, 2015, 21(2):105-112.
[33] WILSON T W, HEINRICHS-GRAHAM E, BECKER K M, et al. Multimodal neuroimaging evidence of alterations in cortical structure and function in HIV-infected older adults[J]. Hum Brain Mapp, 2015, 36(3):897-910.
[34] CORRÊA D G, ZIMMERMANN N, NETTO T M, et al. Regional cerebral gray matter volume in HIV-positive patients with executive function deficits[J]. J Neuroimaging, 2016, 26(4):450-457.
[35] KÜPER M, RABE K, ESSER S, et al. Structural gray and white matter changes in patients with HIV[J]. J Neurol, 2011, 258(6):1066-1075.
[36] BECKER J T, MARUCA V, KINGSLEY L A, et al. Factors affecting brain structure in men with HIV disease in the post-HAART era[J]. Neuroradiology, 2012, 54(2):113-121.
[37] ZHOU Y W, LI R L, WANG X X, et al. Motor-related brain abnormalities in HIV-infected patients:a multimodal MRI study[J]. Neuroradiology, 2017, 59(11):1133-1142.
[38] ABE H, MEHRAEIN P, WEIS S. Degeneration of the cerebellar dentate nucleus and the inferior olivary nuclei in HIV-1-infected brains:a morphometric analysis[J]. Acta Neuropathol, 1996, 92(2):150-155.
[39] KLUNDER A D, CHIANG M C, DUTTON R A, et al. Mapping cerebellar degeneration in HIV/AIDS[J]. Neuroreport, 2008, 19(17):1655-1659.
[40] TOWGOOD K J, PITKANEN M, KULASEGARAM R, et al. Mapping the brain in younger and older asymptomatic HIV-1 men:frontal volume changes in the absence of other cortical or diffusion tensor abnormalities[J]. Cortex, 2012, 48(2):230-241.
[41] WILEY C A, MASLIAH E, MOREY M, et al. Neocortical damage during HIV infection[J]. Ann Neurol, 1991, 29(6):651-657.
[42] VALCOUR V, CHALERMCHAI T, SAILASUTA N, et al. Central nervous system viral invasion and inflammation during acute HIV infection[J]. J Infect Dis, 2012, 206(2):275-282.
[43] GRAY F, SCARAVILLI F, EVERALL I, et al. Neuropathology of early HIV-1 infection[J]. Brain Pathol, 1996, 6(1):1-15.
[44] OZDENER H. Molecular mechanisms of HIV-1 associated neurodegeneration[J]. J Biosci, 2005, 30(3):391-405.
[45] SARMA M K, NAGARAJAN R, KELLER M A, et al. Regional brain gray and white matter changes in perinatally HIV-infected adolescents[J]. Neuroimage Clin, 2014, 4:29-34.
[46] HINKIN C H, VAN GORP W G, MANDELKERN M A, et al. Cerebral metabolic change in patients with AIDS:report of a six-month follow-up using positron-emission tomography[J]. J Neuropsychiatry Clin Neurosci, 1995, 7(2):180-187.
[47] ROTTENBERG D A, MOELLER J R, STROTHER S C, et al. The metabolic pathology of the AIDS dementia complex[J]. Ann Neurol, 1987, 22(6):700-706.
[48] ROTTENBERG D A, SIDTIS J J, STROTHER S C, et al. Abnormal cerebral glucose metabolism in HIV-1 seropositive subjects with and without dementia[J]. J Nucl Med, 1996, 37(7):1133-1141.
[49] VAN GORP W G, MANDELKERN M A, GEE M, et al. Cerebral metabolic dysfunction in AIDS:findings in a sample with and without dementia[J]. J Neuropsychiatry Clin Neurosci, 1992, 4(3):280-287.
[50] VON GIESEN H J, ANTKE C, HEFTER H, et al. Potential time course of human immunodeficiency virus type 1-associated minor motor deficits:electrophysiologic and positron emission tomography findings[J]. Arch Neurol, 2000, 57(11):1601-1607.
[51] HUA X, BOYLE C P, HAREZLAK J, et al. Disrupted cerebral metabolite levels and lower nadir CD4+counts are linked to brain volume deficits in 210 HIV-infected patients on stable treatment[J]. Neuroimage Clin, 2013, 3:132-142.
[52] KAUL M, GARDEN G A, LIPTON S A. Pathways to neuronal injury and apoptosis in HIV-associated dementia[J]. Nature, 2001, 410(6831):988-994.
[53] MATTSON M P, HAUGHEY N J, Nath A. Cell death in HIV dementia[J]. Cell Death Differ, 2005, 12(Suppl 1):893-904.
[54] ZHAO M L, KIM M O, MORGELLO S, et al. Expression of inducible nitric oxide synthase, interleukin-1 and caspase-1 in HIV-1 encephalitis[J]. J Neuroimmunol, 2001, 115(1,2):182-191.
[55] ANTHONY I C, RAMAGE S N, CARNIE F W, et al. Influence of HAART on HIV-related CNS disease and neuroinflammation[J]. J Neuropathol Exp Neurol, 2005, 64(6):529-536.
[56] CHANG L, LEE P L, YIANNOUTSOS C T, et al. A multicenter in vivo proton-MRS study of HIV-associated dementia and its relationship to age[J]. Neuroimage, 2004, 23(4):1336-1347.
[57] SANFORD R, FERNANDEZ CRUZ A L, SCOTT S C, et al. Regionally specific brain volumetric and cortical thickness changes in HIV-infected patients in the HAART era[J]. J Acquir Immune Defic Syndr, 2017, 74(5):563-570.
[58] WRIGHT P W, PYAKUREL A, VAIDA F F, et al. Putamen volume and its clinical and neurological correlates in primary HIV infection[J]. Aids, 2016, 30(11):1789-1794.
[59] HEATON R K, FRANKLIN D JR R, DEUTSCH R, et al. Neurocognitive change in the era of HIV combination antiretroviral therapy:the longitudinal CHARTER study[J]. Clin Infect Dis, 2015, 60(3):473-480.
[60] BROUILLETTE M J, YUEN T, FELLOWS L K, et al. Identifying neurocognitive decline at 36 months among HIV-positive participants in the CHARTER cohort using group-based trajectory analysis[J]. PLoS One, 2016, 11(5):e0155766.
[61] SACKTOR N, SKOLASKY R L, SEABERG E, et al. Prevalence of HIV-associated neurocognitive disorders in the multicenter AIDS cohort study[J]. Neurology, 2016, 86(4):334-340.
[62] BONNET F, AMIEVA H, MARQUANT F, et al. Cognitive disorders in HIV-infected patients:are they HIV-related?[J]. Aids, 2013, 27(3):391-400.
[63] COLE J H, UNDERWOOD J, CAAN M W, et al. Increased brain-predicted aging in treated HIV disease[J]. Neurology, 2017, 88(14):1349-1357.
[64] COLE J H, CAAN M W A, UNDERWOOD J, et al. No evidence for accelerated aging-related brain pathology in treated human immunodeficiency virus:longitudinal neuroimaging results from the comorbidity in relation to AIDS (COBRA) project[J]. Clin Infect Dis, 2018, 66(12):1899-1909.
[65] YANG L Q, LIN F C, LEI H. Resting state functional connectivity in brain studied by fMRI approach[J]. Chinese J Magn Reson, 2010, 27(3):326-340.杨丽琴,林富春,雷皓.静息状态下脑功能连接的磁共振成像研究[J].波谱学杂志, 2010, 27(3):326-340.
